 Organic growth rates by business area: Ostomy Care 6%, Continence Care 8% and Urology Care 6%. In Wound &
Skin Care, sales declined by 1% relative to last year.

 Gross profit was up by 12% to DKK 7,345m, bringing the gross Margin to 67% from 65% last year. At constant ex-
change rates, the gross Margin was 66%.

 EBIT was up by 26% to DKK 3,255m. The EBIT Margin was 30% against 25% last year. At constant exchange
rates, the EBIT Margin was 29%.

 The net profit for the year was up by 21% to DKK 2,194m, while earnings per share also improved by 21% relative
to last year to DKK 51.5.

 The free cash flow was up by 28% to DKK 2,336m.

 ROIC after tax was 38%, compared with 30% last year.

 The Board of Directors recommends that the shareholders attending the general meeting to be held on 11 Decem-
ber 2012 approve the following proposals:
o to pay a dividend of DKK 20 per share (FY 2010/11: DKK 14), equal to a pay-out ratio of 38%.
o that the Board of Directors be authorised to pay extraordinary dividend during the financial year, if war-
ranted by the company's cash position.
o to make a 1-to-5 Split of the Coloplast share. This will change the nominal Value per share from DKK 5 to
DKK 1.
o that the share capital be reduced by a nominal Value of DKK 5m, equal to 1,000,000 shares each with a
nominal Value of DKK 5.